The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis.
 
Hiroe Kayatani
Honoraria - Ono Pharmaceutical
 
Keisuke Aoe
Research Funding - AstraZeneca Japan; Bristol-Myers Squibb Japan; Lilly; Novartis; Ono Pharmaceutical
 
Kadoaki Ohashi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical
Research Funding - Boehringer Ingelheim; Lilly Japan; Novartis
 
Hiroshige Yoshioka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Akihiro Bessho
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyorin; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Kyorin (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Nobuhisa Ishikawa
No Relationships to Disclose
 
Masahiro Yamasaki
No Relationships to Disclose
 
Toshiyuki Kozuki
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Merck Serono (Inst)
 
Nobukazu Fujimoto
Honoraria - Astellas Pharma; Chugai Pharma; Daiichi Sankyo; Hisamitsu Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Kyorin; Ono Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Hisamitsu Pharmaceutical (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Yutaka Ueda
No Relationships to Disclose
 
Syuuji Bandoh
No Relationships to Disclose
 
Isao Murakami
No Relationships to Disclose
 
Hirohisa Ichikawa
No Relationships to Disclose
 
Tetsuya Kubota
No Relationships to Disclose
 
Keisuke Sugimoto
No Relationships to Disclose
 
Nagio Takigawa
Research Funding - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; MSD; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
 
Takashi Sumikawa
No Relationships to Disclose
 
Katsuyuki Kiura
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Momotaro Gene Inc.; Nippon Kayaku; Ono Pharmaceutical; Pfizer